Drug profile

The FDA adverse-event record for Canine Adenovirus Type 2,Toronto A/26/61,Live + Canine Coronavirus,K-378/51,Live + Canine Distemper,Vcp258,Vector + Canine Parainfluenza Virus,D-008,Live + Canine Parvovirus,780916,Live

Name: Canine Adenovirus Type 2,Toronto A/26/61,Live + Canine Coronavirus,K-378/51,Live + Canine Distemper,Vcp258,Vector + Canine Parainfluenza Virus,D-008,Live + Canine Parvovirus,780916,Live - FDA Animal Adverse Event Reports
Creator: PlainBreed
License: https://creativecommons.org/publicdomain/zero/1.0/

18 FDA reports name Canine Adenovirus Type 2,Toronto A/26/61,Live + Canine Coronavirus,K-378/51,Live + Canine Distemper,Vcp258,Vector + Canine Parainfluenza Virus,D-008,Live + Canine Parvovirus,780916,Live, a lower-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#1890 of 2,679
by report volume (all drugs): 18
adverse-event reports: 33.3%
death-coded share: Dog
most-reported species

Compiled by PlainBreed

Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Canine Adenovirus Type 2,Toronto A/26/61,Live + Canine Coronavirus,K-378/51,Live + Canine Distemper,Vcp258,Vector + Canine Parainfluenza Virus,D-008,Live + Canine Parvovirus,780916,Live ranks #1884 of 2679 by total reports (18). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1): 97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1): #1884
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Canine Adenovirus Type 2,Toronto A/26/61,Live + Canine Coronavirus,K-378/51,Live + Canine Distemper,Vcp258,Vector + Canine Parainfluenza Virus,D-008,Live + Canine Parvovirus,780916,Live has 18 reports now versus 18 in that prior snapshot: 0 the same number of (0.0%).

Report change: +0
Death-coded reports: +0
Death-coded share: +0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Canine Adenovirus Type 2,Toronto A/26/61,Live + Canine Coronavirus,K-378/51,Live + Canine Distemper,Vcp258,Vector + Canine Parainfluenza Virus,D-008,Live + Canine Parvovirus,780916,Live changes

Signature read: Canine Adenovirus Type 2,Toronto A/26/61,Live + Canine Coronavirus,K-378/51,Live + Canine Distemper,Vcp258,Vector + Canine Parainfluenza Virus,D-008,Live + Canine Parvovirus,780916,Live's 33.3% death-coded share is among the highest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.

Total Reports

Deaths Reported

33.3%

Death-coded share of reports

Active Ingredients

Canine Adenovirus Type 2,Toronto A/26/61,LiveCanine Coronavirus,K-378/51,LiveCanine Distemper,Vcp258,VectorCanine Parainfluenza Virus,D-008,LiveCanine Parvovirus,780916,Live

Administration Routes

SubcutaneousUnknown

Species Affected

Dog 18

Most Affected Breeds

Retriever - Labrador 6

Crossbred Canine/dog 1

Boxer (German Boxer) 1

Rottweiler 1

Dog (unknown) 1

Poodle - Toy 1

Bulldog - French 1

Collie - Border 1

Doberman Pinscher 1

Chihuahua 1

Most Reported Reactions

Vomiting 7

Lack of efficacy (virus) - parvovirus (including feline panleukopenia) 6

Death 5

Lethargy (see also Central nervous system depression in 'Neurological') 3

Anaemia NOS 3

Not eating 3

Proprioception deficit 2

Leucocytosis NOS 2

Neutrophilia 2

Fever 2

Elevated serum alkaline phosphatase (ALP) 2

Low blood urea nitrogen (BUN) 2

Outcome Breakdown

Recovered/Normal

7 (36.8%)

Died

5 (26.3%)

Outcome Unknown

4 (21.1%)

Ongoing

2 (10.5%)

Euthanized

1 (5.3%)

Canine Adenovirus Type 2,Toronto A/26/61,Live + Canine Coronavirus,K-378/51,Live + Canine Distemper,Vcp258,Vector + Canine Parainfluenza Virus,D-008,Live + Canine Parvovirus,780916,Live: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
Browse the full drug directory to compare report counts across products. All drugs

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Canine Adenovirus Type 2,Toronto A/26/61,Live + Canine Coronavirus,K-378/51,Live + Canine Distemper,Vcp258,Vector + Canine Parainfluenza Virus,D-008,Live + Canine Parvovirus,780916,Live (#1890 of 2,679 by report volume); death-coded 33.3%. PlainBreed drug row · death-coded share stamp 33.3% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →